Rethinking carnitine palmitoyltransferase II and liver stem cells in metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma

doi:10.3748/wjg.v31.i15.104528

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (117)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Sum=104

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=5

Apr 21, 2025 (publication date) through Apr 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Letter to the Editor

World J Gastroenterol. Apr 21, 2025; 31(15): 104528
Published online Apr 21, 2025. doi: 10.3748/wjg.v31.i15.104528

Full Size Figure Download Figure

Figure 1 Schematic representation of the role of mitochondrial dysfunction in the progression of metabolic dysfunction-associated fatty liver disease to hepatocellular carcinoma. CPT II: Carnitine palmitoyltransferase II; FFA: Free fatty acid; HCC: Hepatocellular carcinoma; LCSC: Liver cancer stem cell; MAFLD: Metabolic dysfunction-associated fatty liver disease; MMP: Mitochondrial membrane potential.

Citation: Cai H, Yang CH, Gao P. Rethinking carnitine palmitoyltransferase II and liver stem cells in metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma. World J Gastroenterol 2025; 31(15): 104528
URL: https://www.wjgnet.com/1007-9327/full/v31/i15/104528.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i15.104528